Tortoise Investment Management LLC Has $67,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Tortoise Investment Management LLC lessened its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 41.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,376 shares of the biopharmaceutical company’s stock after selling 969 shares during the period. Tortoise Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $67,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Addison Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 6.6% during the 3rd quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 192 shares in the last quarter. Symphony Financial Ltd. Co. boosted its position in Bristol-Myers Squibb by 4.1% in the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 194 shares during the last quarter. AMG National Trust Bank grew its stake in Bristol-Myers Squibb by 1.0% in the 3rd quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock valued at $1,143,000 after purchasing an additional 201 shares during the period. Westside Investment Management Inc. raised its stake in shares of Bristol-Myers Squibb by 2.9% during the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 204 shares during the period. Finally, HHM Wealth Advisors LLC grew its position in Bristol-Myers Squibb by 9.3% during the third quarter. HHM Wealth Advisors LLC now owns 2,399 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 205 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.2 %

Shares of NYSE BMY traded down $0.08 on Friday, reaching $44.03. 15,787,957 shares of the company’s stock traded hands, compared to its average volume of 14,696,859. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The business’s 50 day simple moving average is $48.91 and its two-hundred day simple moving average is $50.00. Bristol-Myers Squibb has a 12 month low of $43.33 and a 12 month high of $67.16. The company has a market cap of $89.25 billion, a price-to-earnings ratio of -14.20, a price-to-earnings-growth ratio of 14.91 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.05 EPS. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.45%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Finally, BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $60.00.

Check Out Our Latest Report on BMY

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.